Algernon Pharmaceuticals Inc. (AGNPF)
USD 0.05
(3.65%)
USD 0.05
(3.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.01 Million CAD | 38.15% |
| 2022 | -5.98 Million CAD | 25.68% |
| 2021 | -8.05 Million CAD | 7.97% |
| 2020 | -8.74 Million CAD | -354.36% |
| 2019 | -1.92 Million CAD | -103.0% |
| 2018 | -948.55 Thousand CAD | 5.72% |
| 2017 | -1 Million CAD | 65.72% |
| 2016 | -2.93 Million CAD | -301.73% |
| 2015 | -730.46 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1 Million CAD | -92.39% |
| 2024 Q3 | -465.66 Thousand CAD | 55.96% |
| 2024 Q1 | -521.97 Thousand CAD | 47.05% |
| 2023 Q1 | -1.88 Million CAD | 15.21% |
| 2023 Q4 | -985.84 Thousand CAD | 12.6% |
| 2023 FY | -3.7 Million CAD | 38.15% |
| 2023 Q3 | -1.12 Million CAD | 9.6% |
| 2023 Q2 | -1.24 Million CAD | 33.64% |
| 2022 Q1 | -1.2 Million CAD | -119.95% |
| 2022 Q4 | -2.21 Million CAD | -176.8% |
| 2022 Q3 | -801.16 Thousand CAD | 56.38% |
| 2022 Q2 | -1.83 Million CAD | -52.92% |
| 2022 FY | -5.98 Million CAD | 25.68% |
| 2021 Q4 | -546.03 Thousand CAD | 67.43% |
| 2021 Q3 | -1.67 Million CAD | 29.81% |
| 2021 FY | -8.05 Million CAD | 7.97% |
| 2021 Q2 | -2.38 Million CAD | 30.59% |
| 2021 Q1 | -3.44 Million CAD | -20.36% |
| 2020 Q2 | -795.14 Thousand CAD | -129.57% |
| 2020 FY | -8.74 Million CAD | -354.36% |
| 2020 Q3 | -4.6 Million CAD | -479.11% |
| 2020 Q4 | -2.85 Million CAD | 37.92% |
| 2020 Q1 | -346.36 Thousand CAD | 19.89% |
| 2019 Q4 | -432.34 Thousand CAD | 18.85% |
| 2019 Q2 | -446.99 Thousand CAD | 14.05% |
| 2019 Q1 | -520.08 Thousand CAD | -168.13% |
| 2019 FY | -1.92 Million CAD | -103.0% |
| 2019 Q3 | -532.76 Thousand CAD | -19.19% |
| 2018 Q1 | -196.25 Thousand CAD | 33.29% |
| 2018 FY | -948.55 Thousand CAD | 5.72% |
| 2018 Q4 | -193.96 Thousand CAD | 51.2% |
| 2018 Q3 | -397.46 Thousand CAD | -147.08% |
| 2018 Q2 | -160.86 Thousand CAD | 18.04% |
| 2017 Q3 | -310.41 Thousand CAD | 4.69% |
| 2017 FY | -1 Million CAD | 65.72% |
| 2017 Q4 | -294.21 Thousand CAD | 5.22% |
| 2017 Q1 | -508.46 Thousand CAD | -82.82% |
| 2017 Q2 | -325.68 Thousand CAD | 35.95% |
| 2016 Q1 | -160.64 Thousand CAD | 69.5% |
| 2016 Q4 | -278.12 Thousand CAD | 41.14% |
| 2016 Q3 | -472.51 Thousand CAD | 76.65% |
| 2016 Q2 | -2.02 Million CAD | -1159.46% |
| 2016 FY | -2.93 Million CAD | -301.73% |
| 2015 Q3 | -203.79 Thousand CAD | 0.0% |
| 2015 Q4 | -526.67 Thousand CAD | -158.44% |
| 2015 FY | -730.46 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -31.358% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 93.01% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1817.293% |
| SQZ Biotechnologies Company | -75.82 Million USD | 93.382% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -76.041% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 71.883% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 106.131% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -226.686% |
| Marizyme, Inc. | -34.08 Million USD | 85.278% |
| Genus plc | 6.4 Million USD | 178.407% |
| Pharming Group N.V. | -4.87 Million USD | -2.839% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -152.611% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -438.776% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 39.904% |
| ContraFect Corporation | -56.88 Million USD | 91.179% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -257.923% |
| IMV Inc. | -38.67 Million USD | 87.024% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -82.419% |
| ONE Bio Corp. | 13.68 Million USD | 136.678% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 91.493% |
| Mesoblast Limited | -84.14 Million USD | 94.037% |
| MultiCell Technologies, Inc. | -722.81 USD | -694142.609% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 241.753% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.793% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1188.101% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -90.981% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 202.101% |
| Biomind Labs Inc. | -1 Million USD | -397.032% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -72.962% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 24.518% |
| Skye Bioscience, Inc. | -13.67 Million USD | 63.296% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -169.156% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 151.507% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -16653.656% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -10.172% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 0.524% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 68.38% |
| Accustem Sciences Inc. | -3.74 Million USD | -33.943% |
| EV Biologics, Inc. | -483.06 Thousand USD | -938.801% |
| Q BioMed Inc. | -3.44 Million USD | -45.636% |
| GB Sciences, Inc. | -1.42 Million USD | -253.258% |
| Alpha Cognition Inc. | -9.7 Million USD | 48.297% |
| CSL Limited | 3.7 Billion USD | 100.136% |
| Agentix Corp. | -1.37 Million USD | -265.813% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 90.872% |
| Enzolytics Inc. | -2.14 Million USD | -133.528% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 60.64% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -58.385% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -159.652% |
| argenx SE | -425.04 Million USD | 98.819% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 90.96% |
| HST Global, Inc. | -140.9 Thousand USD | -3461.253% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -380.657% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -346.087% |
| Halberd Corporation | -75.05 Thousand USD | -6586.282% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -71.884% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -47.374% |
| Zenith Capital Corp. | -8.94 Million USD | 43.888% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -217.728% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -104.375% |
| AVAX Technologies, Inc. | 6.69 Million USD | 174.976% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2825.817% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -150.307% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -28704.632% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -103.427% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -409.937% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -299.527% |
| Kadimastem Ltd | -3.04 Million USD | -65.054% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 35.492% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2664.997% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -275.763% |
| LadRx Corporation | -3.82 Million USD | -31.238% |
| Cell Source, Inc. | -4.32 Million USD | -16.015% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1107.776% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -630.483% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -630.483% |
| Affymax, Inc. | -15.04 Million USD | 66.649% |
| Mobile Lads Corp. | -554.55 Thousand USD | -804.888% |
| Itoco Inc. | -919.14 Thousand USD | -445.951% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -18.395% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -348.441% |
| International Stem Cell Corporation | -663 Thousand USD | -656.871% |
| CytoDyn Inc. | -18.05 Million USD | 72.211% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -19836.651% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -2180.126% |
| Qrons Inc. | -643.67 Thousand USD | -679.592% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -788.587% |
| SYBLEU INC | -149.18 Thousand USD | -3263.759% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -125.037% |
| Rebus Holdings, Inc. | -664 Thousand USD | -655.731% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -176.276% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -9432.779% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -24570.87% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 86.163% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -210.139% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -581.954% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -61.3% |
| Neutra Corp. | -229.48 Thousand USD | -2086.65% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 71.389% |
| PureTech Health plc | -146.19 Million USD | 96.568% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 76.651% |
| IXICO plc | -1.43 Million USD | -249.204% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 47.128% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 95.88% |
| CSL Limited | 3.81 Billion USD | 100.132% |
| Cellectis S.A. | -108.85 Million USD | 95.39% |